Personal information

Verified email domains

Sweden, United States, Switzerland

Biography

Dr. Gaspard Pardon graduated with a MSc in Microengineering from EPFL in 2008, and obtain his PhD in Electrical Engineering - Micro and Nanosystems from KTH Royal Institute of Technology in Stockholm, Sweden. His graduate research focussed on the engineering of novel micro- and nanofluidic devices and approaches for rapid Point-of-Care diagnostics of infectious diseases, including the detection of airborne pathogens.

In 2016, Gaspard moved to the Silicon Valley in California where he conducted postdocs at Stanford University. He worked on the development of novel in vitro cardiac models, a.k.a. organ-on-chip or microphysiological systems, using cardiac cells differentiated from human induced pluripotent stem cells (hiPSCs). He focussed his research and technological developments on the study of genetic cardiomyopathies, including Duchenne Muscular Dystrophy, studying the impact of tissue stiffness on cellular biomechanics, telomere shortening and disease progression.

Since March 2021, Gaspard joined EPFL Swiss Institute of Technology in Lausanne to establish and direct the Bioengineering and Organoids Technology platform at the AGORA Cancer Research Center. This hybrid platform aims to provide infrastructure and scientific support in the use, development and translation of bioengineering technologies. It fosters cross-disciplinary collaborations around bioengineering between the researchers from the partner institution: CHUV, HUG, UNIL, EPFL, Ludwig Cancer Research Center and ISREC, as well as with industrial partners in the biotech and pharma industry.

Activities

Employment (5)

EPFL: Lausanne, CH

2021-03-01 to present | Head of Unit (Life Sciences)
Employment
Source: Self-asserted source
Gaspard Pardon

Stanford University School of Medicine: Stanford, California, US

2018-09-01 to 2020-12-31 | Postdoctoral Research Fellow (M&I, BAXTER LABORATORY FOR STEM CELL BIOLOGY)
Employment
Source: Self-asserted source
Gaspard Pardon

Stanford University: Stanford, California, US

2017-09-01 to 2018-08-31 | Postdoctoral Research Fellow (Bioengineering)
Employment
Source: Self-asserted source
Gaspard Pardon

Stanford University: Stanford, CA, US

2016-09-01 to 2017-08-31 | Postdoctoral research fellow (Mechanical Engineering)
Employment
Source: Self-asserted source
Gaspard Pardon

Royal Institute of Technology: Stockholm, SE

2014-06-01 to 2017-08-31 | Postdoktor (Micro and Nanosystems)
Employment
Source: Self-asserted source
Gaspard Pardon

Funding (7)

Bio-repository of protein-based growth factors and genome editing tools for organoids research

2023-04 to 2024-10 | Grant
École Polytechnique Fédérale de Lausanne (Lausanne, CH)
Source: Self-asserted source
Gaspard Pardon

A microfluidic workstation to guide clinical oncotherapy by functionally assaying drug sensitivity and drug combinations directly on patient tumour cells

2023-01 to 2024-04 | Grant
École Polytechnique Fédérale de Lausanne (Lausanne, CH)
Source: Self-asserted source
Gaspard Pardon

Swiss Personalized Oncology National Data Stream (SPO-NDS)

2022-09 to 2025-08 | Grant
Swiss Academy of Medical Sciences (Bern, CH)
GRANT_NUMBER:

NDS-2021-906

Source: Self-asserted source
Gaspard Pardon

Automation of cultures, handling and assay of patient-derived tumor organoids and tissue explants through robotics and microfluidics

2022-08 to 2024-01 | Grant
École Polytechnique Fédérale de Lausanne (Lausanne, CH)
Source: Self-asserted source
Gaspard Pardon

Outside-in and Inside-out mechanosignaling in cardiomyopathy onset and progression

2018-07-01 to 2020-06-30 | Grant
American Heart Association (Dallas, US)
GRANT_NUMBER:

18POST34080160

Source: Self-asserted source
Gaspard Pardon via DimensionsWizard

Manipulating the microenvironment to study outside-in mechanosignaling in cardiomyopathy onset and progression using cardiomyocytes derived from human stem cells

2018-07-01 to 2018-12-31 | Grant
Swiss National Science Foundation (Bern, CH)
GRANT_NUMBER: 180825
Source: Self-asserted source
Gaspard Pardon via DimensionsWizard

Enabling with microfluidics the use of human-induced pluripotent stem-cell cardiomyocyte (hiPSC-CM) as a model for high-throughput cardiotoxicity and cardiomyopathy studies at the single cell level

2016-09-01 to 2018-02-28 | Grant
Swiss National Science Foundation (Bern, CH)
GRANT_NUMBER: 164954
Source: Self-asserted source
Gaspard Pardon via DimensionsWizard